6IB Stock Chart & Stats
€9.81
-€0.15(-1.51%)
At close: 4:00 PM EDT
€9.81
-€0.15(-1.51%)
Day’s Range― - ―
52-Week Range€7.91 - €12.10
Previous CloseN/A
Volume0.00
Average Volume (3M)532.00
Market Cap
€19.10B
Enterprise Value€122.92K
Total Cash (Recent Filing)€18.24B
Total Debt (Recent Filing)€2.82B
Price to Earnings (P/E)133.0
Beta0.25
Next Earnings
Mar 31, 2027EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding1,743,682,600
10 Day Avg. Volume172
30 Day Avg. Volume532
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)6.12
Price to Sales (P/S)9.09
P/FCF Ratio12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.45Price Target Upside47.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)0.13
Revenue Forecast (FY)€1.97B
Bulls Say, Bears Say
Bulls Say
Revenue And Margin InflectionThe 2025 revenue increase, sharp gross-margin improvement and return to profitability indicate stronger commercial execution. Sustaining these gains would improve operating leverage and provide a broader earnings base for funding Innovent’s pipeline.
Strong Cash GenerationThe substantial 2025 cash-flow improvement gives Innovent greater internal funding capacity for clinical development, manufacturing and commercialization. Strong cash conversion can reduce reliance on external financing if performance remains durable.
Pipeline And Commercial PartnershipsThe SP001 license expands Innovent’s potential international economics while preserving Greater China rights, and the Vanflyta arrangement adds a partnered commercial opportunity. These deals broaden future revenue sources beyond the existing portfolio.
Bears Say
Uneven Cash-Flow HistoryAlthough 2025 cash generation was powerful, the preceding period shows inconsistent conversion and sustained free-cash-flow deficits. This history makes it difficult to assume the latest improvement is fully recurring and raises funding risk for ongoing R&D.
Profitability Durability RiskThe return to profit is encouraging but remains relatively modest after several years of operating losses. Continued execution is required to prove that commercial scale, pricing and product mix can support durable earnings rather than a one-year inflection.
Partner Supply DependenceInnovent’s China commercialization opportunity depends on Daiichi Sankyo for key development, manufacturing and supply responsibilities. This division can add expertise, but it also introduces partner coordination and availability risks into execution.
Innovent Biologics News
6IB FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was €7.91 and its highest was €12.10 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is €19.10B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Mar 31, 2027 which is in 215 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Aug 25, 2026. The company reported €0.089 earnings per share for the quarter, beating the consensus estimate of €0.06 by €0.029.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 0.15.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,743,682,600 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of €0.089 in its last earnings report, beating expectations of €0.06. Following the earnings report the stock price went up 3.906%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in DE:6IB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innovent Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€14.45 (47.26% Upside)
€14.45 (47.26% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
86.27%
Trailing 12-Months
Company Description
Innovent Biologics
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
6IB Stock 12 Month Forecast
Average Price Target
€14.45
▲(47.26% Upside)
Technical Analysis
3SBio
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―